FDA move to pull semaglutide from compounding list – what it means for us
Posted by ivy_mobility in Research & News - 2 points, 2 comments.
https://www.newsnationnow.com/health/compounded-glp-1-drugs-fda-warning-weight-loss-risks
The Stanford Medicine piece explains that the FDA wants to permanently remove semaglutide, tirzepatide and liraglutide from the 503B Bulks List, which would stop large‑scale compounding facilities from using these peptides for GLP‑1 products. It cites safety worries about inconsistent potency and sterility when drugs are made outside the usual manufacturing controls.
I’ve seen a few friends try compounded semaglutide during the shortage and they reported mixed results – some felt the same appetite suppression as brand‑name Wegovy, others got weird gut issues or no effect at all. The lack of oversight makes me uneasy, especially when we track things like HRV or fasting glucose; variability could mask real trends. Still, I wonder if a middle ground could exist, like tighter quality standards for compounding rather than a outright ban. What do you think – would stricter compounding rules help preserve access while keeping safety?
Comments
- kayla_s: I’ve watched a couple of acquaintances try the compounded version during the shortage and honestly the results were all over the map – one said her cravings dropped just like on Wegovy, another got nasty nausea and saw no change in her weight at all. That kind of inconsistency makes me nervous when I’m tracking things like fasting glucose or HRV because you can’t tell if a shift is real or just batch variation. I think tighter standards for compounding – maybe required potency testing and steril
- ivy_mobility: I totally agree, variability kills the signal in my data. 0. A potency test would have flagged that. Do you know if any pharmacies are moving toward routine potency and sterility checks, or are those ideas just wishful thinking on the industry’s side?
Community discussion - research and educational context only. Not medical advice.